NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-633-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50,000.00
Profitability
Miscellaneous
Employees139
OptionableOptionable
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) issued its earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The biotechnology company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.10 million. Nantkwest had a negative return on equity of 54.20% and a negative net margin of 198,790.38%. View Nantkwest's Earnings History.
When is Nantkwest's next earnings date?
What price target have analysts set for NK?
2 equities research analysts have issued 12 month target prices for Nantkwest's stock. Their forecasts range from $2.00 to $3.50. On average, they expect Nantkwest's stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 143.4% from the stock's current price. View Analyst Price Targets for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.
Has Nantkwest been receiving favorable news coverage?
News headlines about NK stock have been trending positive on Monday, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nantkwest earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include MeiraGTx (MGTX), Voyager Therapeutics (VYGR), CASI Pharmaceuticals (CASI), Gamida Cell (GMDA), Gritstone Oncology (GRTS), Krystal Biotech (KRYS), Avrobio (AVRO), Solid Biosciences (SLDB), Eiger Biopharmaceuticals (EIGR), Adverum Biotechnologies (ADVM), Sutro Biopharma (STRO), LogicBio Therapeutics (LOGC), ADMA Biologics (ADMA), Compugen (CGEN) and La Jolla Pharmaceutical (LJPC).
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)
- Mr. Richard J. Tajak, Consultant (Age 65)
- Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 45)
- Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)
When did Nantkwest IPO?
(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.
Who are Nantkwest's major shareholders?
Nantkwest's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.20%), Geode Capital Management LLC (0.42%), Candriam Luxembourg S.C.A. (0.29%), Dimensional Fund Advisors LP (0.29%), D. E. Shaw & Co. Inc. (0.23%) and Bank of New York Mellon Corp (0.13%). View Institutional Ownership Trends for Nantkwest.
Which major investors are selling Nantkwest stock?
Which major investors are buying Nantkwest stock?
NK stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., D. E. Shaw & Co. Inc., Two Sigma Investments LP, SG Americas Securities LLC, Paloma Partners Management Co, Rhumbline Advisers and Geode Capital Management LLC. View Insider Buying and Selling for Nantkwest.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $1.13.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $89.53 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe.
What is Nantkwest's official website?
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
